Phytomedicines as potential inhibitors of β amyloid aggregation: significance to Alzheimer's disease.
10.1016/S1875-5364(14)60122-9
- Author:
N Satheesh KUMAR
1
;
N NISHA
2
Author Information
1. Department of Pharmaceutical Analysis, National Institute of Pharmaceutical Education and Research [NIPER-H], Balanagar, Hyderabad-500037, India. Electronic address: satish@niperhyd.ac.in.
2. Department of Biochemistry, Aurigene Discovery Technologies, Hyderabad-500049, India.
- Publication Type:Journal Article
- Keywords:
Amyloid-beta peptide;
Medicinal plants;
Plant-derived pharmaceuticals;
Thioflavin T;
β amyloid aggregation
- MeSH:
Alzheimer Disease;
drug therapy;
Amyloid beta-Peptides;
Humans;
Plants, Medicinal;
Protein Aggregation, Pathological;
drug therapy
- From:
Chinese Journal of Natural Medicines (English Ed.)
2014;12(11):801-818
- CountryChina
- Language:English
-
Abstract:
Throughout the history of drug development, plants have been an important source for the discovery of novel therapeutically active compounds for many diseases. The ethnopharmacological approach has provided several leads to identify potential new drugs from plant sources, including those for memory disorders. For the treatment of Alzheimer's disease the drug discovery focus shifted from cholinesterase inhibitors, to other targets primarily based on two key neuropathological hallmarks, namely the hyperphosphorylation of the tau protein resulting in the formation of neurofibrillary tangles (NFTs), and the increased formation and aggregation of amyloid-beta peptide (Aβ) derived from amyloid precursor protein (APP). The present article aims to provide a comprehensive literature survey of plants and their constituents that have been tested for Aβ aggregation, thus possibly relieving several features of Alzheimer's disease (AD).
